□□□□□□□:□□□□□

□□□□□

“□□” □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□”□□□□” □□□□□□□□□ 10 □□□□□□□□□□□□□□□□□”□□” □□□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□ (WHO) □□□□□□□□□□□□□□□□□□□□□□□□□□□□□ 1 □□□□WHO □□□□□□□□

□□□□□□□□□□□□□□□□□□□

□□□

□□□□□□□□□□□□□HTA □□□□□□□□□□□□□□

□□□□

[glossary_exclude]□□□□

1. World Health Organisation (2016). ‘Constitution of WHO: principles’. Retrieved 4 July 2021, from https://www.who.int/governance/eb/who_constitution_en.pdf
2. World Health Organisation (2000). *The World Health Report 2000. Health Systems: Improving Performance*. Geneva: World Health Organisation. Retrieved 11 February, 2016, from https://www.who.int/whr/2000/en/whr00_en.pdf
3. INAHTA (2016). ‘What is Health Technology Assessment (HTA)?’ Retrieved 11 February, 2016, from http://www.inahta.org/
4. ‘What is Health Technology Assessment (HTA)?’ *Common Questions*. Retrieved 8 August, 2021, from https://www.eunethta.eu/about-eunethta/
5. European Commission (2004). ‘Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.’ Retrieved 11 February, 2016, from http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32004R0726[/glossary_exclude]

A2-6.01.1-v1.1